Abstract
Motile and non-motile cilia are critical to mammalian development and health. Assembly of these organelles depends on proteins synthesized in the cell body and transported into the cilium by intraflagellar transport (IFT). A series of human and mouse IFT74 variants were studied to understand the function of this IFT subunit. Humans missing exon 2, which codes for the first 40 residues, presented an unusual combination of ciliary chondrodysplasia and mucociliary clearance disorders while individuals carrying biallelic splice site variants developed a lethal skeletal chondrodysplasia. In mice, variants thought to remove all Ift74 function, completely block ciliary assembly and result in midgestational lethality. A mouse allele that removes the first 40 amino acids, analogous to the human exon 2 deletion, results in a motile cilia phenotype with mild skeletal abnormalities. In vitro studies suggest that the first 40 amino acids of IFT74 are dispensable for binding of other IFT subunits but are important for tubulin binding. Higher demands on tubulin transport in motile cilia compared to primary cilia could account for the motile cilia phenotype observed in human and mice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MS acknowledges funding from the European Research Council (ERC) (ERC starting grant No. 716344 to MS) and from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project ID 431984000 SFB 1453) and Germany Excellence Strategy CIBSS EXC 2189 project ID 390939984 under Germany Excellence Strategy. GJP funding was provided by National Institutes of Health grant R01 GM060992
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Ethics commitee of the Institute of Child Health, University College London, London UK (GOSH R&D number 11MM03, REC number 08/H0713/82) the ethics committee Arnhem-Nijmegen, The Netherland (ethical approval no 2006-048) and the ethics commitee of Freiburg University, Freiburg, Germany (votum no 122/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- ATD
- Asphyxiating Thoracic Dystrophy
- BBS
- Bardet–Biedl syndrome
- CED
- Cranioectodermal Dysplasia
- DAPI
- 4′,6-diamidino-2-phenylindole
- E
- embryonic day
- JBTS
- Joubert syndrome
- MEFs
- Mouse embryonic fibroblasts
- P
- postnatal day
- PCD
- Primary Ciliary Dyskinesia
- SRPS
- Short-Rib Polydactyly Syndrome